中国肺癌杂志Issue(10)：524-528,5.DOI:10.3779/j.issn.1009-3419.2013.10.05
EGFR-TKIs治疗晚期非小细胞肺癌获益后出现缓慢进展的治疗选择：附32例病例总结
Treatment Choice for Advanced Non-small Cell Lung Cancer Patients Who Had Gradual Progression After EGFR-TKIs:32 Cases Report
摘要
Abstract
Background and objective hTe epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in the treatment of the advanced non-small cell lung cancer (NSCLC), especially in the adeno-carcinoma patients with activating EGFR mutations. But there is no published overview of the following treatment. hTis report through observing the efficacy, toxicity and overall survival of different treatments to the advanced NSCLC patients who had gradual progression atfer EGFR-TKIs, evaluates the inlfuence of the continued treatment and switching chemotherapy. Methods Retrospective review is conducted on 32 cases of advanced NSCLC patients who experienced treatment failure of EGFR-TKIs. One group accepted the continued treatment and the other group accepted the switching chemotherapy. Results hTe median overall survival of the continued treatment group is 36.0 months. hTe respose rate of the switching chemotherapy group is 43.75%, and clinical benefit rate (complete and partial response and stable disease) is 87.5%. The median overall survival is 15.5 months. hTe main toxicities are nausea, vomiting and hematological toxicities. Conclusion For the advanced NSCLC patients who had gradual progression atfer EGFR-TKIs, the continued treatment is one of the acceptable choices.关键词
肺肿瘤/EGFR-TKIs/缓慢进展/生存期Key words
Lung neoplasms/EGFR-TKIs/Gradual progression/Overall survival引用本文复制引用
林琳,王彬,郝学志,邢镨元,李峻岭,张湘茹,石远凯..EGFR-TKIs治疗晚期非小细胞肺癌获益后出现缓慢进展的治疗选择：附32例病例总结[J].中国肺癌杂志,2013,(10):524-528,5.基金项目
本研究受国家“重大新药创制”科技重大专项“十一?五”课题（No.2008ZX09312-020）；国家“重大新药创制”科技重大专项“十二?五”课题（No.2012ZX09303-012）；北京市科技计划项目（No.Z111102071011001）；中央保健课题（No.B2009B124）资助 （）
